About Veloxis
Veloxis is a company based in Edison (United States) founded in 2002 was acquired by Asahi Kasei in November 2019.. The company has 54 employees as of December 31, 2020. Veloxis offers products and services including VEL-101 and Therapy Pipeline. Veloxis operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Edison, United States
- Employees 54 as on 31 Dec, 2020
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Veloxis Pharmaceuticals, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$60 M (USD), Debt – Conventional
Feb 14, 2018
-
Investors
Athyrium Capital Management
& 1 more
-
Employee Count
54
as on Dec 31, 2020
-
Acquired by
Asahi Kasei
(Nov 25, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Veloxis
Veloxis offers a comprehensive portfolio of products and services, including VEL-101 and Therapy Pipeline. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational agent for maintaining immunosuppression in transplant patients.
Collection of new therapies targeting transplant medicine challenges.
Unlock access to complete
Unlock access to complete
Board Team
2 people
Operations Team
2 people
Sales and Marketing
1 people
Chairman Team
1 people
Unlock access to complete
Funding Insights of Veloxis
- Total Funding Total Funding
- Total Rounds 1
- Last Round Debt – Conventional — $60.0M
-
First Round
First Round
(14 Feb 2018)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2018 | Amount | Debt – Conventional - Veloxis | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Veloxis
Veloxis has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Athyrium Capital Management and Asahi Kasei. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Veloxis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Veloxis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Veloxis Comparisons
Competitors of Veloxis
Veloxis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Veloxis
Frequently Asked Questions about Veloxis
When was Veloxis founded?
Veloxis was founded in 2002 and raised its 1st funding round 16 years after it was founded.
Where is Veloxis located?
Veloxis is headquartered in Edison, United States. It is registered at Edison, New Jersey, United States.
Who is the current CEO of Veloxis?
Mark Hensley is the current CEO of Veloxis.
How many employees does Veloxis have?
As of Dec 31, 2020, the latest employee count at Veloxis is 54.
What does Veloxis do?
Veloxis Pharmaceuticals was established in 2002 and is headquartered in Edison, United States. Focus is placed on specialty pharmaceuticals targeting cardiovascular conditions and organ transplantation. Key products include Envarus, an extended-release tacrolimus tablet, and Fenoglide, whose commercial rights have been licensed to Valeant Pharma. Proprietary MeltDose technology is employed to improve oral bioavailability and enable controlled drug release, especially for poorly water-soluble compounds.
Who are the top competitors of Veloxis?
Veloxis's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
What products or services does Veloxis offer?
Veloxis offers VEL-101 and Therapy Pipeline.
Who are Veloxis's investors?
Veloxis has 2 investors. Key investors include Athyrium Capital Management, and Asahi Kasei.